title: Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study.
abstract: Growth factors (GF) stimulate cell proliferation through binding to cell membrane receptors and are thought to be involved in cancer risk and survival. We examined how genetic variation in epidermal growth factor (EGF), neuregulin 2 (NRG2), ERBB2 (HER2/neu), fibroblast growth factors 1 and 2 (FGF1 and FGF2) and its receptor 2 (FGFR2), and platelet-derived growth factor B (PDGFB) independently and collectively influence breast cancer risk and survival. We analyzed data from the Breast Cancer Health Disparities Study which includes Hispanic (2,111 cases, 2,597 controls) and non-Hispanic white (1,481 cases, 1,586 controls) women. Adaptive rank-truncated product (ARTP) analysis was conducted to determine gene significance. Odds ratios (OR) and 95 % confidence intervals were obtained from conditional logistic regression models to estimate breast cancer risk and Cox proportional hazard models were used to estimate hazard ratios (HR) of dying from breast cancer. We assessed Native American (NA) ancestry using 104 ancestry informative markers. We observed few significant associations with breast cancer risk overall or by menopausal status other than for FGFR2 rs2981582. This SNP was significantly associated with ER+/PR+ (OR 1.66, 95 % CI 1.37-2.00) and ER+/PR- (OR 1.54, 95 % CI 1.03-2.31) tumors. Multiple SNPs in FGF1, FGF2, and NRG2 significantly interacted with multiple SNPs in EGFR, ERBB2, FGFR2, and PDGFB, suggesting that breast cancer risk is dependent on the collective effects of genetic variants in other GFs. Both FGF1 and ERBB2 significantly influenced overall survival, especially among women with low levels of NA ancestry (P ARTP = 0.007 and 0.003, respectively). Our findings suggest that genetic variants in growth factors signaling appear to influence breast cancer risk through their combined effects. Genetic variation in ERBB2 and FGF1 appear to be associated with survival after diagnosis with breast cancer.
authors.affiliation: Department of Medicine, University of Utah, 383 Colorow, Salt Lake City, UT 84108, USA. marty.slattery@hsc.utah.edu
authors.forename: Martha L
authors.initials: ML
authors.lastname: Slattery
authors.forename: Esther M
authors.initials: EM
authors.lastname: John
authors.forename: Mariana C
authors.initials: MC
authors.lastname: Stern
authors.forename: Jennifer
authors.initials: J
authors.lastname: Herrick
authors.forename: Abbie
authors.initials: A
authors.lastname: Lundgreen
authors.forename: Anna R
authors.initials: AR
authors.lastname: Giuliano
authors.forename: Lisa
authors.initials: L
authors.lastname: Hines
authors.forename: Kathy B
authors.initials: KB
authors.lastname: Baumgartner
authors.forename: Gabriela
authors.initials: G
authors.lastname: Torres-Mejia
authors.forename: Roger K
authors.initials: RK
authors.lastname: Wolff
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality*; D016022:Case-Control Studies; D004815:Epidermal Growth Factor / Q000235:genetics; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000235:genetics; D016222:Fibroblast Growth Factor 2 / Q000235:genetics; D018734:Genes, erbB-2; D020571:Genes, sis; D006630:Hispanic or Latino / Q000235:genetics; D006801:Humans; D007198:Indians, North American / Q000235:genetics; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics*; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000235:genetics; D044465:White People / Q000235:genetics
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; C106766:NRG2 protein, human; D009414:Nerve Growth Factors; D016222:Fibroblast Growth Factor 2; D016220:Fibroblast Growth Factor 1; D004815:Epidermal Growth Factor; C496353:FGFR2 protein, human; D051497:Receptor, Fibroblast Growth Factor, Type 2
references.citation: Circulation. 1994 Aug;90(2):649-52
references.pmid: 8044933
references.citation: Carcinogenesis. 2013 Aug;34(8):1787-93
references.pmid: 23563089
references.citation: Clin Chem Lab Med. 2012 Oct 1;50(10):1809-18
references.pmid: 23089711
references.citation: Breast Cancer Res Treat. 2013 Jan;137(2):559-69
references.pmid: 23225170
references.citation: Cancer Lett. 2008 Feb 8;259(2):146-55
references.pmid: 18006148
references.citation: Carcinogenesis. 2010 Aug;31(8):1417-23
references.pmid: 20554749
references.citation: Med Clin (Barc). 2007 Jul 7;129(6):218-21
references.pmid: 17678604
references.citation: Int J Oncol. 2003 Feb;22(2):237-52
references.pmid: 12527919
references.citation: Oncogenesis. 2012 Jul 02;1:e16
references.pmid: 23552733
references.citation: Am J Clin Pathol. 2010 Mar;133(3):416-29
references.pmid: 20154280
references.citation: Genetics. 2000 Jun;155(2):945-59
references.pmid: 10835412
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1143-52
references.pmid: 14652273
references.citation: Genet Epidemiol. 2009 Dec;33(8):700-9
references.pmid: 19333968
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):33-41
references.pmid: 21119072
references.citation: Mol Carcinog. 2013 Nov;52 Suppl 1:E52-9
references.pmid: 23143756
references.citation: Breast Cancer Res Treat. 2012 Jun;133(2):769-78
references.pmid: 22315135
references.citation: Cancer Res. 1986 Mar;46(3):1015-29
references.pmid: 3002607
references.citation: Cold Spring Harb Perspect Med. 2012 Dec 01;2(12):a006676
references.pmid: 23209177
references.citation: Cancer Epidemiol. 2011 Dec;35(6):503-9
references.pmid: 21474413
references.citation: Br J Cancer. 2008 Oct 21;99(8):1357-63
references.pmid: 18827819
references.citation: Breast Cancer Res Treat. 2010 Nov;124(2):521-8
references.pmid: 20364400
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):261-4
references.pmid: 15668504
references.citation: Nat Genet. 2007 Jul;39(7):870-4
references.pmid: 17529973
references.citation: Breast Cancer Res Treat. 1994 Jan;29(1):29-40
references.pmid: 8018962
references.citation: Am J Physiol. 1991 Dec;261(6 Pt 1):L378-85
references.pmid: 1767858
references.citation: Breast Cancer Res Treat. 2007 Mar;102(1):85-101
references.pmid: 17080310
references.citation: Immunogenetics. 2012 Jan;64(1):71-6
references.pmid: 21822685
references.citation: Anticancer Res. 1995 Nov-Dec;15(6B):2627-31
references.pmid: 8669837
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2905-13
references.pmid: 16365008
references.citation: Carcinogenesis. 2012 Aug;33(8):1512-21
references.pmid: 22562547
references.citation: Breast Cancer Res Treat. 2008 Sep;111(2):321-7
references.pmid: 17940864
references.citation: Genetics. 2003 Aug;164(4):1567-87
references.pmid: 12930761